EGFR and non-small cell lung carcinoma: JO25567, NEJ026, CTONG1509, and RELAY studies have shown that the combination of EGFR‐TKIs with antiangiogenic inhibitors (e.g., bevacizumab, anlotinib, ramucirumab) may have prolonged PFS in advanced EGFR‐mutant NSCLC compared with EGFR‐TKIs monotherapy, although these studies have not yielded OS benefit.279, 280, 281, 282